In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 6550-6550
Abstract:
6550 Background: Disparities in clinical trials limit the generalizability of study findings and perpetuate disparities in treatment access and outcomes, but there is a paucity of data in the Canadian context. The objective of this study was to examine disparities in cancer clinical trial enrollment at a large, comprehensive Canadian cancer center. Methods: We conducted a retrospective cohort study of clinical trial enrollment among all newly diagnosed cancer patients (N=154,880) at the Princess Margaret Cancer Centre in Toronto, Canada (2006-2021). Multivariable Bayesian hierarchical logistic regression with random effect for most responsible physician was used to examine the correlates of clinical trial enrollment, comparing the population of enrolled and non-enrolled patients. Odds ratios were adjusted for patient variables (sex, age at diagnosis, language, geography, primary care provider), and census tract-level marginalization (residential instability, material deprivation, dependency, ethnic concentration), disease variables (cancer site and disease stage at diagnosis), and provider variables (most responsible physician (MRP), and MRP’s sex, language, medical training, and department). Results: Overall, 11.2% of patients enrolled (n=17,400) in a clinical trial, with 5-, 10-, and 15-year cumulative incidences of 12%, 15%, and 18%, respectively. Small, but significant differences were observed between enrollees and the overall patient population. Lower odds of enrollment were observed in patients who were female (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI] , 0.78-0.86; p 〈 .001), ≥65 years (AOR vs 〈 40, 0.61; 95% CI, 0.56-0.65; p 〈 .001), non-English language speakers (AOR vs English, 0.72; 95% CI, 0.67-0.77; p 〈 .001), lived ≥250 km away from the cancer center (AOR vs 〈 15km, 0.71; 95% CI, 0.62-0.80; p 〈 .001), or lived in areas with greater material deprivation (AOR, 0.94; 95% CI, 0.93-0.96; p 〈 .001) or higher ethnic concentration (AOR, 0.96; 95% CI, 0.94-0.98; p 〈 .001). Greater odds of enrollment were found in patients with metastatic disease (AOR, 1.19; 95% CI, 1.13-1.25; p 〈 .001) and in those with a primary care provider (AOR, 1.69; 95% CI, 1.55-1.85; p 〈 .001). Conclusions: Disparities were observed in clinical trial enrollment, despite a publicly funded health care system. While broader prospective data collection efforts are critical to better understand the influence of patient, provider and system factors on clinical trial enrollment, these findings suggest the need for targeted strategies to increase diversity in clinical trial access.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2023.41.16_suppl.6550
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2023
detail.hit.zdb_id:
2005181-5
Permalink
